XCath, with support from UAE’s Crescent Enterprises, achieves world-first robotic brain aneurysm surgery, marking a new milestone in neurovascular robotics.
SHARJAH: In a major global medical breakthrough, XCath, backed by UAE-based Crescent Enterprises, has successfully completed the world’s first robotic brain aneurysm surgeries. The procedures, conducted at The Panama Clinic by Dr. Vitor Mendes Pereira and Dr. Anastasio Ameijeiras Sibauste, mark the first-ever human use of XCath’s revolutionary endovascular robotic (EVR) system to treat complex intracranial conditions.
This historic achievement places the UAE at the forefront of global medical technology innovation. XCath’s EVR is now the only neurovascular robotic system capable of real intracranial navigation, pushing the boundaries of what’s possible in brain surgery. Notably, it is the world’s first triaxial neurovascular robot capable of intervention.
Crescent Enterprises, a Sharjah-headquartered diversified investment firm, played a pivotal role in this success as XCath’s founding and largest shareholder. The achievement builds on earlier milestones, including a public remote thrombectomy demo during Abu Dhabi Global Healthcare Week in 2024, where a blood clot was removed remotely from South Korea in real time.
The implications are profound. Brain aneurysms, which affect 1 in 50 people globally, require sub-millimetre precision for safe intervention. With most patients receiving treatment too late, robotic systems like XCath’s could democratise access, especially in regions lacking neuro-specialists. The technology enables “bringing the specialist to the patient,” drastically reducing critical delays.
Dr. Pereira, lead surgeon on the trial, praised the precision and consistency offered by robotic assistance, noting its transformative potential for junior doctors and its role in reducing surgical risks. With aneurysm rupture often fatal or severely disabling, this robotic milestone offers new hope for safer, faster, and more accessible treatment options.
As XCath gears up for commercial and remote neurointervention applications, this success not only reinforces the UAE’s commitment to healthcare innovation but also signals a future where life-saving surgery is both scalable and globally accessible.
